Confirmed Sponsors

We thank to our partners!

Title Partner

PRO.MED.CS is a leading Czech pharmaceutical company with its own human medicines research and development centre. PRO.MED.CS specializes in manufacturing tablets, coated tablets and capsules, with daily production exceeding two million units.

PRO.MED.CS’s 50 brands of medicines are sold on more than 30 markets. Our specialty is gastroenterology, with GIT medications accounting for more than half of sales. Other areas of focus are the cardiovascular system and CNS. The company’s portfolio primarily comprises prescription medicines.

PRO.MED.CS’s in-house research and development team and quality assessment system ensure that all medicinal products meet the highest standards of quality.

Dr. Bares Awards

Since 1993, PRO.MED.CS has been organizing a biannual competition for the best research papers in the fields of gastroenterology and hepatology. In 2005 the competition was named the Dr. Bares Award in honour of Dr. Rudolf Bares, the founder and long-serving CEO of PRO.MED.CS and a patron of gastroenterology.

Clinical Trial Collaborations

PRO.MED.CS is collaborating with University College London on a clinical trial studying the effects of Ambrosan in patients with Parkinson’s disease. The company has also joined forces with the University of Sheffield to run a clinical trial examining the effects of Ursosan in patients with Parkinson’s disease.

Organization and Event Sponsorship

PRO.MED.CS is a long-term sponsor of the Learned Society of the Czech Republic. To facilitate exchanges of experience amongst experts from throughout Europe, the Russian Federation, and Central Asia, we fund and take active part in events that bring together researchers to discuss the latest medical findings. PRO.MED.CS regularly participates in United European Gastroenterology Week and organizes the International Symposium of Gastroenterology (ISG), a meeting focusing on sharing best practices and presenting recent advances and treatment methods in the field of gastroenterology since 1995.

General Partner

AGROFERT, spol. s r.o., was established on 25 January 1993 as a company focused on the fertiliser trade. At the time of its establishment, the company had 4 employees. Currently, the AGROFERT Group comprises 199 companies controlled and managed, 1 jointly controlled company and 6 companies under significant influence; 23 companies are excluded from the consolidation. AGROFERT Group companies are active in the fields of chemicals, agriculture and primary production, food processing, forestry and wood processing, land technology and engineering, logistics and transport, renewable resources and media.

Madeta a.s. is the largest milk processor in the Czech Republic. It has been operating on the market for more than 100 years and has undergone great development during that time. Madeta is 4 in 1! Four individual factories that are very close to each other, not only from a local point of view. They process more than half a billion liters of milk a year, which is a fifth of total production in the Czech Republic. Each has its own “speciality” – products that can be produced there and nowhere else. Madeta totally produces 239 kinds of products with an annual volume of 350 million pieces. All are without artificial preservatives.

Approximately a quarter of our production is exported abroad, to Lebanon, to United Arab Emirates, European Union countries, Asia, Africa and to America.

About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

About Gilead Sciences in Liver Disease
For more than 20 years, Gilead has sought to address some of the biggest challenges in liver disease. The company has transformed the trajectory of many liver diseases through a relentless pursuit of innovation and pioneering access programs to bring meaningful therapies to people around the world. More work is required, and Gilead is committed to advancing innovative therapeutics to address the most pressing unmet needs in liver disease and overcoming barriers to better care.

Transforming lives with less-invasive technologies engineered to diagnose and treat a wide range of medical conditions. We’re dedicated to collaborating with healthcare professionals to develop a broad portfolio of meaningful innovations that improve outcomes, reduce costs, increase efficiencies and—most importantly—help more people in more places around the world live longer, healthier lives.

Astellas Pharma s.r.o. is part of Astellas Pharma Inc., a global company that is one of the world's 20 leading pharmaceutical corporations. Astellas employs approximately 15,000 people worldwide whose mission is to improve lives through reliable and innovative pharmaceutical products.

Astellas Pharma was formed in 2005 by the merger of Yamanouchi and Fujisawa. Both companies have built a great reputation in selected therapeutic areas during their independent operation, mainly due to the high quality, efficacy and safety of their original medicines, and by their mergers have created a solid foundation for a company with a high level of research and development and sustainable growth in the global pharmaceutical industry.

Astellas Europe's key therapeutic areas include transplantation, urology and the treatment of infectious diseases. Astellas is also committed to further developing its portfolio, specifically in the therapeutic field of oncology and related unmet needs.

Platinum Partner

AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, as well as through our Allergan Aesthetics portfolio.

We care deeply for patients and customers, their families, our employees, and our communities. We strive to always do the right thing, pursuing the highest standards in quality, compliance, safety, and performance. We embrace diverse backgrounds and perspectives and treat everyone equally, with dignity and respect, allowing us all to achieve our best.

Our commitment to health doesn’t stop with our medicines. Each day, we work to deliver sustainable solutions that improve the health of our business and the health of humankind.

For more information about AbbVie, please visit us at www.abbvie.cz.

Bronze Partner

International Medical Press (IMP) specializes in providing independent and accredited medical education activities funded through unrestricted educational grants. IMP has extensive experience in medical education, is backed by enduring relationships with faculty and provides strong scientific support across several therapy areas.

IMP is a founding partner of the Good CME Practice (gCMEp) Group that is committed to delivering patient-centred, balanced and effective medical education.

Main Partner

We are a leading global biopharmaceutical company. For over 130 years, MSD has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives. Our drug research and development is based on innovation and scientific precision. Therapeutic areas in the Czech Republic: oncology, vaccines, infectious disease, immunology, diabetes and cardiovascular disease.